Bro­ken promis­es? FDA needs more pow­er to re­move drugs from mar­ket­place, JA­MA analy­sis finds

The FDA is strug­gling to re­move drugs from the mar­ket­place that don’t show ef­fec­tive­ness in late stage tri­als, new JA­MA analy­ses found, thanks to the per­sis­tent ten­sion be­tween speed and con­fi­dence in ear­ly clin­i­cal da­ta.

Con­gress, reg­u­lat­ed in­dus­try and pa­tients have urged the FDA to short­en the amount of time that the mar­ket has to wait for drugs to be­come avail­able that may help se­vere and preva­lent dis­eases – and the FDA has lis­tened, of­fer­ing up a quick ac­cel­er­at­ed ap­proval path­way that’s fre­quent­ly used by new can­cer drugs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER